A carregar...

Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors

Dipeptidyl-peptidase-IV (DPP-4) inhibitors have become an important orally active drug class for the treatment of type 2 diabetes as second-line therapy after metformin failure or as monotherapy or combination therapy with other drugs when metformin is not tolerated or contraindicated. DPP-4 inhibit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Autor principal: Gallwitz, Baptist
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3666443/
https://ncbi.nlm.nih.gov/pubmed/23730503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042018813486165
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!